Clinical Trials | December 04, 2025
Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis
The company is excluding data from the affected sites to maintain the study's integrity
The company is excluding data from the affected sites to maintain the study's integrity
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Subscribe To Our Newsletter & Stay Updated
